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Running head: Cannabis Shenanigans

Cannabis is an effective pain reliever that should be available to patients and
researchers1-3. Because of the international conventions, cannabis is currently listed as a
Schedule I drug indicating that it has no medical value and a high risk of abuse and dependence.
These conventions were politically expedient and largely driven by the United States against the
advice of the physicians present4-6. At no time during these conventions was there any attempt
to investigate the commercial or medicinal properties of cannabis. It was politically expedient
to utilize propaganda7-9 and racial fear10 to forge a political wall that impedes access and form a
major barrier to medical research into cannabis use. The major argument against the
rescheduling of cannabis is that there is research is not convincing11. This argument is
disingenuous at best, given that the evidence has been presented and rejected at many points
during the political dialogue5, 12 restricting funding for research. Moreover, there was no
scientific or medical data utilized in the decisions to criminalize cannabis.
Human beings have peacefully coexisted with cannabis for at least 10,200 years 13.
Trade in cannabis as food, fiber and medicine 14 is evident long before the first written record of
medical use around 2,700 BC 15. During the 19th century, western medicine rediscovered the
healing properties of cannabis

16, 17.

However, international alarm over an opium epidemic

brewed a global political storm that led to a reaction against opium and “Indian hemp”
cultivation and exportation in the early 20th century4 that was influenced by the temperance
movement of the previous century18. In this current opioid epidemic, it is ironic that some of
the first recorded uses of cannabis in western medicine showed its effectiveness in treating
persons with opioid addiction17.

The 1912 international opium convention and the 1925 International Commishion on
Dangerous Drugs pressed countries to restrict import and export of opium and cannabis;
signatories’ instituted laws restricting the trafficking of opium and cannabis by way of taxation
and certification. The US, China and Japan requested that the medical and scientific properties
of cannabis and opium be investigated, but the other countries voted the request down4. The
United States response was the 1937 Marijuana Tax Act that levied exorbitant taxes for the
prescription of cannabis in the US 19.
Cannabis remained in medical use until it was removed from the U.S. pharmacopoeia in
194115. Subsequent legislative action of criminalizing marijuana possession in the Boggs act in
1951 which introduced mandatory minimum sentencing for cannabis possession 20, 21. Cannabis
use for over 10,000 years became criminal activity in the US less than 70 years ago based on
absolutely no evidence22. The final political victory was found in the Single Convention on
Narcotic Drugs 1961 and 197223. This convention mandated that the 100 signatory countries
would classify cannabis as having no medical value despite a great deal of evidence to the
contrary5, 6 .
Published research has completely eroded the claim that cannabis has no medicinal
value. The discovery of the endocannabinoid system indicates the observed medicinal
properties of cannabis have a biological basis for action 24. The National Academies report that
there is conclusive evidence of the effectiveness of cannabis for controlling chronic pain, 1
nausea, and spasticity 2; and has natural control over pain pathways, its withdraw symptoms
are very mild 25 compared to alcohol, opiates or benzodiazepines.

Chronic pain affects up to 83% 26-28 of persons living with SCI; 58% of these patient
report the pain is excruciating 29, 30. Chronic pain limits activities of daily life (ADL) 31, 32; leads to
poorer overall health, lower satisfaction with quality of life 33 and; a greater risk of developing
depression 34. A Cochrane review found only poor quality evidence supporting the long term
efficacy of opioids and other pain killers in chronic pain patients35and contribute to the current
crisis of misuse of prescription drugs 36-38.
The patient voice is clear. Patients with SCI and chronic pain report that cannabis was
the single most effective medication out of 26 pain treatments and the fourth longest acting
pain relief 27, 39. Eighty-one percent of patients strongly agreed that cannabis alone was more
effective for pain than cannabis and opioids 37. Others report relief of pain in 75-83 % medical
cannabis patients 38, 40-43 and 92% of the patients reported improved quality of life 44 after other
treatment have failed. There is no difference in the occurrence of serious adverse events
compared to control 45. With an overall adult lifetime dependence rate of 9% of cannabis users
46,

drug researchers have consistently listed cannabis as less addictive than caffeine, nicotine

and alcohol; placing cannabis last or near the last in a list of addictive drugs 47, 48.
This evidence shows that cannabis is not a schedule I drug. It indeed has substantial
medicinal value in a wide variety of conditions, is less addictive then other drugs and has a very
low lifetime dependence rate. The misclassification of cannabis by international convention
motivated by political bodies49 has created a unique situation researchers. The moratorium on
federally funded cannabis research leaves clinicians with little scientific base when counseling
patients who may be interested in using cannabis for medical reasons. We have no standard

dosing ranges, or warning labels like on tobacco or alcohol. It also leads to a dearth of solid
evidence to formulate clinical trials.
The time has come to put the cannabis discussion in a human rights framework50.
Ethically, it is unjust to withhold and restrict the use of a potentially effective drug, when the
typical medication can be ineffective, has a high risk of addiction and could lead to overdose35.
“Seriously ill patients have the right to effective therapies. To deny patients access to such a
therapy is to deny them dignity and respect as person51.”
People with SCI should feel free to discuss cannabis use with physicians, regardless of
the legality or method of acquisition, just as they would discuss supplement use or over-thecounter medications. They should also feel confident that physicians would have accurate and
helpful information about the possible risks and benefits of cannabis to help make informed
decisions that best suit the person’s lifestyle. Currently this information is not readily available
for physicians.
There is tension between the needs of a society to protect the vulnerable by restricting
the rights of others to live well and with less pain. It is clear that this 70-year war on cannabis
has had little effect in controlling the supply of cannabis. Prohibition can never succeed, “It is a
tyranny from which every independent mind revolts18.” People living with chronic pain should
not have to risk social stigma, restrictions on employment and even criminal prosecution in
order to deal with their pain52.
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poisoning

International opium commishion 1909
Interational opium convention 1912
Pushed taxation and control of import and export
international commishion on dangerous drugs 1925
The use of Indian hemp and the preparations derived therefrom may only be authorized for medical
and scientific purposes. The raw resin (charas), however, which is extracted from the female
tops of the cannabis sativa L, together with the various preparations (hashish, chira, esrar,
diamba, etc.) of which it forms the basis, not being at present utilized for medical purposes
and only being susceptible of utilisation for harmful purposes, in the same manner as other
narcotics, may not be produced, sold, traded in, etc., under any circumstances whatsoever.
Single convention on Narcotic drugs 1961, 1972

Derogable

1909
Interational opium convention
Pushed taxation and control of import and export

Bone human right to use cannabis global
prohibitition of cannabis potential not fully understood.

international commishion on dangerous drugs 1925.
The use of Indian hemp and the preparations derived therefrom may only be authorized for medical
and scientific purposes. The raw resin (charas), however, which is extracted from the female
tops of the cannabis sativa L, together with the various preparations (hashish, chira, esrar,
diamba, etc.) of which it forms the basis, not being at present utilized for medical purposes
and only being susceptible of utilisation for harmful purposes, in the same manner as other
narcotics, may not be produced, sold, traded in, etc., under any circumstances whatsoever.
Single convention on Narcotic drugs 1961, 1972

